Titre : Salicylate de sodium

Salicylate de sodium : Questions médicales fréquentes

Termes MeSH sélectionnés :

Probability
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Salicylate de sodium : Questions médicales les plus fréquentes", "headline": "Salicylate de sodium : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Salicylate de sodium : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-04", "dateModified": "2025-04-29", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Salicylate de sodium" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Acide salicylique", "url": "https://questionsmedicales.fr/mesh/D020156", "about": { "@type": "MedicalCondition", "name": "Acide salicylique", "code": { "@type": "MedicalCode", "code": "D020156", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.455.426.559.389.657.410.595.608" } } }, "about": { "@type": "MedicalCondition", "name": "Salicylate de sodium", "alternateName": "Sodium Salicylate", "code": { "@type": "MedicalCode", "code": "D012980", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "L K Mamedova", "url": "https://questionsmedicales.fr/author/L%20K%20Mamedova", "affiliation": { "@type": "Organization", "name": "Department of Animal Sciences and Industry, Kansas State University, Manhattan 66506." } }, { "@type": "Person", "name": "B J Bradford", "url": "https://questionsmedicales.fr/author/B%20J%20Bradford", "affiliation": { "@type": "Organization", "name": "Department of Animal Sciences and Industry, Kansas State University, Manhattan 66506. Electronic address: bbradfor@ksu.edu." } }, { "@type": "Person", "name": "Yasmina M Abd-Elhakim", "url": "https://questionsmedicales.fr/author/Yasmina%20M%20Abd-Elhakim", "affiliation": { "@type": "Organization", "name": "Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt. Electronic address: yasmina_forensic@hotmail.com." } }, { "@type": "Person", "name": "Attia A A Moselhy", "url": "https://questionsmedicales.fr/author/Attia%20A%20A%20Moselhy", "affiliation": { "@type": "Organization", "name": "Department of Anatomy and Embryology, Faculty of Veterinary Medicine, Zagazig University, Egypt." } }, { "@type": "Person", "name": "Rasha R Beheiry", "url": "https://questionsmedicales.fr/author/Rasha%20R%20Beheiry", "affiliation": { "@type": "Organization", "name": "Department of Histology and Cytology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Comparison of Survival Outcomes Between Larynx-Preserving Open Partial Pharyngectomy and Radiotherapy or Chemoradiotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Single-Center Retrospective Analysis with Inverse Probability of Treatment Weighting Adjustments.", "datePublished": "2023-07-14", "url": "https://questionsmedicales.fr/article/37452169", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1245/s10434-023-13934-1" } }, { "@type": "ScholarlyArticle", "name": "Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.", "datePublished": "2024-04-29", "url": "https://questionsmedicales.fr/article/38756630", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.21037/jgo-24-218" } }, { "@type": "ScholarlyArticle", "name": "Intensity-modulated proton and carbon-ion radiotherapy using fixed-beam system for locally advanced lung cancer: dosimetric comparison with x-ray radiotherapy and normal tissue complication probability (NTCP) evaluation.", "datePublished": "2023-12-08", "url": "https://questionsmedicales.fr/article/38064747", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1088/1361-6560/ad13d1" } }, { "@type": "ScholarlyArticle", "name": "A glycosylated hemoglobin A1c above 6% (42 mmol/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis.", "datePublished": "2023-06-02", "url": "https://questionsmedicales.fr/article/37271306", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.diabet.2023.101455" } }, { "@type": "ScholarlyArticle", "name": "Proteomic profiling reveals KRT6C as a probable hereterodimer partner for KRT9: New insights into re-classifying epidermolytic palmoplantar keratoderma (EPPK) and a milder form of pachyonychia congenita (PC-K6c) as a group of genetic cutaneous disorders.", "datePublished": "2023-07-17", "url": "https://questionsmedicales.fr/article/37467889", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jprot.2023.104971" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés chimiques organiques", "item": "https://questionsmedicales.fr/mesh/D009930" }, { "@type": "ListItem", "position": 3, "name": "Hydrocarbures", "item": "https://questionsmedicales.fr/mesh/D006838" }, { "@type": "ListItem", "position": 4, "name": "Hydrocarbures cycliques", "item": "https://questionsmedicales.fr/mesh/D006844" }, { "@type": "ListItem", "position": 5, "name": "Hydrocarbures aromatiques", "item": "https://questionsmedicales.fr/mesh/D006841" }, { "@type": "ListItem", "position": 6, "name": "Dérivés du benzène", "item": "https://questionsmedicales.fr/mesh/D001555" }, { "@type": "ListItem", "position": 7, "name": "Phénols", "item": "https://questionsmedicales.fr/mesh/D010636" }, { "@type": "ListItem", "position": 8, "name": "Hydroxybenzoates", "item": "https://questionsmedicales.fr/mesh/D062385" }, { "@type": "ListItem", "position": 9, "name": "Salicylates", "item": "https://questionsmedicales.fr/mesh/D012459" }, { "@type": "ListItem", "position": 10, "name": "Acide salicylique", "item": "https://questionsmedicales.fr/mesh/D020156" }, { "@type": "ListItem", "position": 11, "name": "Salicylate de sodium", "item": "https://questionsmedicales.fr/mesh/D012980" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Salicylate de sodium - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Salicylate de sodium", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Salicylate de sodium", "description": "Comment diagnostiquer une intoxication au salicylate de sodium ?\nQuels tests sont utilisés pour évaluer l'efficacité du salicylate de sodium ?\nQuels symptômes indiquent un surdosage de salicylate de sodium ?\nComment différencier le salicylate de sodium d'autres AINS ?\nQuels antécédents médicaux sont pertinents pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D012980?mesh_terms=Probability&page=275#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Salicylate de sodium", "description": "Quels sont les effets secondaires courants du salicylate de sodium ?\nLe salicylate de sodium peut-il provoquer des réactions allergiques ?\nQuels symptômes indiquent une réaction sévère au salicylate de sodium ?\nComment le salicylate de sodium affecte-t-il le système digestif ?\nLe salicylate de sodium peut-il causer des troubles auditifs ?", "url": "https://questionsmedicales.fr/mesh/D012980?mesh_terms=Probability&page=275#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Salicylate de sodium", "description": "Comment prévenir les effets secondaires du salicylate de sodium ?\nY a-t-il des interactions médicamenteuses à surveiller ?\nLes personnes âgées doivent-elles être prudentes avec le salicylate de sodium ?\nComment éviter une surdose de salicylate de sodium ?\nLe salicylate de sodium est-il sûr pendant la grossesse ?", "url": "https://questionsmedicales.fr/mesh/D012980?mesh_terms=Probability&page=275#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Salicylate de sodium", "description": "Comment traiter une intoxication au salicylate de sodium ?\nLe salicylate de sodium est-il utilisé pour traiter l'arthrite ?\nQuelles alternatives existent au salicylate de sodium ?\nComment le salicylate de sodium est-il administré ?\nLe salicylate de sodium nécessite-t-il une prescription ?", "url": "https://questionsmedicales.fr/mesh/D012980?mesh_terms=Probability&page=275#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Salicylate de sodium", "description": "Quelles complications peuvent survenir avec le salicylate de sodium ?\nLe salicylate de sodium peut-il causer des problèmes rénaux ?\nComment le salicylate de sodium affecte-t-il le foie ?\nQuelles sont les conséquences d'un surdosage ?\nLe salicylate de sodium peut-il affecter la coagulation sanguine ?", "url": "https://questionsmedicales.fr/mesh/D012980?mesh_terms=Probability&page=275#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Salicylate de sodium", "description": "Qui est à risque d'effets secondaires du salicylate de sodium ?\nLes enfants peuvent-ils prendre du salicylate de sodium ?\nLes personnes atteintes de maladies cardiaques doivent-elles éviter le salicylate ?\nLe salicylate de sodium est-il sûr pour les personnes allergiques ?\nLes personnes âgées sont-elles plus sensibles au salicylate de sodium ?", "url": "https://questionsmedicales.fr/mesh/D012980?mesh_terms=Probability&page=275#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une intoxication au salicylate de sodium ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic repose sur l'historique médical et des tests sanguins pour mesurer les niveaux de salicylate." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'efficacité du salicylate de sodium ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de douleur et d'inflammation, ainsi que des évaluations cliniques, sont utilisés." } }, { "@type": "Question", "name": "Quels symptômes indiquent un surdosage de salicylate de sodium ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des vertiges, des acouphènes, des nausées et des troubles respiratoires." } }, { "@type": "Question", "name": "Comment différencier le salicylate de sodium d'autres AINS ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Le salicylate de sodium a des propriétés anti-inflammatoires spécifiques et un profil d'effets secondaires distinct." } }, { "@type": "Question", "name": "Quels antécédents médicaux sont pertinents pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents de troubles gastro-intestinaux ou d'allergies aux salicylates sont importants." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants du salicylate de sodium ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent des troubles gastro-intestinaux, des vertiges et des éruptions cutanées." } }, { "@type": "Question", "name": "Le salicylate de sodium peut-il provoquer des réactions allergiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines personnes peuvent développer des réactions allergiques, comme des éruptions cutanées." } }, { "@type": "Question", "name": "Quels symptômes indiquent une réaction sévère au salicylate de sodium ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des difficultés respiratoires ou un gonflement du visage nécessitent une attention médicale immédiate." } }, { "@type": "Question", "name": "Comment le salicylate de sodium affecte-t-il le système digestif ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Il peut provoquer des irritations gastriques, des ulcères ou des saignements gastro-intestinaux." } }, { "@type": "Question", "name": "Le salicylate de sodium peut-il causer des troubles auditifs ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des acouphènes ou une perte auditive temporaire peuvent survenir avec un surdosage." } }, { "@type": "Question", "name": "Comment prévenir les effets secondaires du salicylate de sodium ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Pour prévenir les effets secondaires, il est conseillé de suivre les doses recommandées et de consulter un médecin." } }, { "@type": "Question", "name": "Y a-t-il des interactions médicamenteuses à surveiller ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le salicylate de sodium peut interagir avec des anticoagulants et d'autres AINS." } }, { "@type": "Question", "name": "Les personnes âgées doivent-elles être prudentes avec le salicylate de sodium ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées sont plus susceptibles de subir des effets secondaires et doivent être surveillées." } }, { "@type": "Question", "name": "Comment éviter une surdose de salicylate de sodium ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Respectez toujours les doses prescrites et évitez l'automédication sans avis médical." } }, { "@type": "Question", "name": "Le salicylate de sodium est-il sûr pendant la grossesse ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Son utilisation pendant la grossesse doit être discutée avec un médecin en raison des risques potentiels." } }, { "@type": "Question", "name": "Comment traiter une intoxication au salicylate de sodium ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement peut inclure l'administration de charbon actif et une surveillance médicale étroite." } }, { "@type": "Question", "name": "Le salicylate de sodium est-il utilisé pour traiter l'arthrite ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est souvent prescrit pour soulager la douleur et l'inflammation associées à l'arthrite." } }, { "@type": "Question", "name": "Quelles alternatives existent au salicylate de sodium ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "D'autres AINS comme l'ibuprofène ou le naproxène peuvent être utilisés comme alternatives." } }, { "@type": "Question", "name": "Comment le salicylate de sodium est-il administré ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Il peut être administré par voie orale sous forme de comprimés ou de solutions liquides." } }, { "@type": "Question", "name": "Le salicylate de sodium nécessite-t-il une prescription ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Il peut être disponible sans ordonnance, mais une consultation médicale est recommandée." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le salicylate de sodium ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des saignements gastro-intestinaux, des ulcères et des réactions allergiques graves." } }, { "@type": "Question", "name": "Le salicylate de sodium peut-il causer des problèmes rénaux ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une utilisation prolongée peut entraîner des problèmes rénaux, surtout chez les personnes à risque." } }, { "@type": "Question", "name": "Comment le salicylate de sodium affecte-t-il le foie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des doses élevées peuvent causer des dommages hépatiques, nécessitant une surveillance régulière." } }, { "@type": "Question", "name": "Quelles sont les conséquences d'un surdosage ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Un surdosage peut entraîner des troubles respiratoires, des convulsions et un coma dans les cas graves." } }, { "@type": "Question", "name": "Le salicylate de sodium peut-il affecter la coagulation sanguine ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut affecter la coagulation, augmentant le risque de saignement, surtout avec d'autres anticoagulants." } }, { "@type": "Question", "name": "Qui est à risque d'effets secondaires du salicylate de sodium ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes ayant des antécédents d'ulcères, d'allergies ou de maladies rénales sont à risque." } }, { "@type": "Question", "name": "Les enfants peuvent-ils prendre du salicylate de sodium ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "L'utilisation chez les enfants doit être évitée en raison du risque de syndrome de Reye." } }, { "@type": "Question", "name": "Les personnes atteintes de maladies cardiaques doivent-elles éviter le salicylate ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles doivent consulter un médecin avant de l'utiliser en raison des risques cardiovasculaires." } }, { "@type": "Question", "name": "Le salicylate de sodium est-il sûr pour les personnes allergiques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Non, les personnes allergiques aux salicylates doivent éviter son utilisation pour prévenir des réactions." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus sensibles au salicylate de sodium ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent être plus sensibles aux effets secondaires et nécessitent une surveillance." } } ] } ] }

Sources (2758 au total)

Comparison of Survival Outcomes Between Larynx-Preserving Open Partial Pharyngectomy and Radiotherapy or Chemoradiotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Single-Center Retrospective Analysis with Inverse Probability of Treatment Weighting Adjustments.

There is a group of hypopharyngeal squamous cell carcinoma (HPSCC) patients for whom larynx-preserving open partial pharyngectomy (PP) and radiotherapy/chemoradiotherapy (RT/CRT) are indicated. We aim... This study evaluated HPSCC patients who were initially treated by PP or RT/CRT at our institution between January 2007 and October 2019. Overall survival (OS), disease-specific survival (DSS), larynge... Overall, 198 patients were enrolled; 63 and 135 underwent PP and RT/CRT, respectively. IPTW-adjusted 5-year OS, DSS, LFS, and LRFS rates in the PP and RT/CRT groups were 84.3% and 61.9% (p = 0.019), 8... Despite the risk of bias related to unadjusted factors, our results suggest that PP is associated with significantly better OS and LFS compared with RT/CRT for HPSCC....

Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.

While surufatinib, sunitinib, and everolimus have shown efficacy for advanced neuroendocrine neoplasms (NENs) in randomized controlled trials (RCTs), direct comparisons in a real-world setting remain ... A retrospective, observational study was conducted at Fudan University Shanghai Cancer Center, including patients with advanced NENs treated with surufatinib, sunitinib, or everolimus between July 202... The study enrolled 123, 56, and 68 locally advanced or metastatic NEN patients treated with surufatinib, sunitinib, and everolimus, respectively. Before adjusting for confounding factors, surufatinib ... In a real-world Chinese cohort, surufatinib significantly outperformed sunitinib and everolimus in prolonging PFS among advanced NEN patients, with identifiable clinical features impacting survival, a...

A glycosylated hemoglobin A1c above 6% (42 mmol/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis.

The classical glycosylated hemoglobin A1c threshold of 6.5% is an insensitive screening test for cystic fibrosis-related diabetes (CFRD). We sought to identify CF-specific A1C thresholds associated wi... We studied the cross sectional and longitudinal associations between A1c, BMI, and FEV1 in 2 cohorts of 223 children (followed for up to 8 years) and 289 adults (followed for a mean of 7.5 ± 4.3 years... For the onset of OGTT-defined CFRD optimal A1c threshold was 5.9% in adults (sensitivity: 67% and specificity: 71%) and 5.7% for children (sensitivity: 60% and specificity: 47%). Kaplan-Meier analysis... An A1C above 6% may be associated with a high risk of developing CFRD and a lower probability of weight gain in both adults and children with CF....

Proteomic profiling reveals KRT6C as a probable hereterodimer partner for KRT9: New insights into re-classifying epidermolytic palmoplantar keratoderma (EPPK) and a milder form of pachyonychia congenita (PC-K6c) as a group of genetic cutaneous disorders.

Epidermolytic palmoplantar keratoderma (EPPK), a highly penetrant autosomal dominant genodermatosis, is characterized by diffuse keratoses on palmplantar epidermis. The keratin 9 gene (KRT9) is respon...

Cluster-Based Toxicity Estimation of Osteoradionecrosis via Unsupervised Machine Learning: Moving Beyond Single Dose-Parameter Normal Tissue Complication Probability by Using Whole Dose-Volume Histograms for Cohort Risk Stratification.

Given the limitations of extant models for normal tissue complication probability estimation for osteoradionecrosis (ORN) of the mandible, the purpose of this study was to enrich statistical inference... The analysis was conducted on retrospective data of 1,259 head and neck cancer (HNC) patients treated at XXX between 2005 and 2015. During a minimum 12-month post-therapy follow-up period, 173 patient... The K-means clustering method identified six clusters among the DVHs. Based on the first five clusters, the dose-volume space was partitioned by the soft-margin SVM into distinct regions with differen... This study presents an unsupervised-learning analysis of a large-scale data set to evaluate the risk of mandibular ORN among HNC patients. The results provide a visual risk-assessment tool for ORN (ba...

Long-term oral administration of Huaier granules improves survival outcomes in hepatocellular carcinoma patients within Milan criteria following microwave ablation: a propensity score matching and stabilized inverse probability weighting analysis.

This study aimed to elucidate the therapeutic effects of Huaier granules on hepatocellular carcinoma (HCC) within the Milan criteria in patients who underwent microwave ablation (MWA).... A total of 228 patients were included, with 97 in the Huaier group and 131 in the control group. We evaluated progression-free survival (PFS), overall survival (OS), and extrahepatic metastasis surviv... Following PSM, the 1-, 3-, and 5-year PFS rates in the Huaier and control groups were 83.5% vs 70.7%, 57.7% vs 42.6%, and 43.6% vs 31.9% (... Huaier granules can reduce the risk of recurrence and improve the OS of patients with HCC within the Milan criteria following MWA. Administering Huaier granules for over 6 months proved beneficial....

Cluster-Based Toxicity Estimation of Osteoradionecrosis via Unsupervised Machine Learning: Moving Beyond Single Dose-Parameter Normal Tissue Complication Probability by Using Whole Dose-Volume Histograms for Cohort Risk Stratification.

Given the limitations of extant models for normal tissue complication probability estimation for osteoradionecrosis (ORN) of the mandible, the purpose of this study was to enrich statistical inference... The analysis was conducted on retrospective data of 1,259 head and neck cancer (HNC) patients treated at the University of Texas MD Anderson Cancer Center between 2005 and 2015. The (structural) clust... The K-means clustering method identified six clusters among the DVHs. Based on the first five clusters, the dose-volume space was partitioned almost perfectly by the soft-margin SVM into distinct regi... This study presents an unsupervised-learning analysis of a large-scale data set to evaluate the risk of mandibular ORN among HNC patients. The results provide a visual risk-assessment tool (based on t...

Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT).

The cardiovascular and renal outcomes of angiotensin-II receptor blocker (ARB) and angiotensin-converting enzyme inhibitor (ACEI) treatment are well-known; however, few studies have evaluated initiati... To emulate a target trial to evaluate the cognitive outcomes of initiating an ARB- vs ACEI-based antihypertensive regimen in individuals at risk for mild cognitive impairment (MCI) and probable dement... Active comparator, new-user observational cohort study design using data from the Systolic Blood Pressure Intervention Trial (SPRINT), conducted November 2010 through July 2018. Marginal cause-specifi... New users of ARB vs ACEI during the first 12 months of trial follow-up.... Composite of adjudicated amnestic MCI or PD.... Of 9361 participants, 727 and 1313 new users of an ARB or ACEI, respectively, with well-balanced baseline characteristics between medication exposure groups after inverse probability weighting (mean [... In this observational cohort study of US adults at high cardiovascular disease risk, there was no difference in the rate of amnestic MCI or PD among new users of an ARB compared with ACEI, although 95...